AZD4547 and FGFR Amplification in Advanced Solid Tumors
Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of a phase I study of AZD4547 in patients with advanced tumors.
Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of a phase I study of AZD4547 in patients with advanced tumors.
Clinical Pearls:
- AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), has demonstrated promise in patients who have FGFR amplification in their tumor.
- FGFR amplification is rare.
- Tumor biology is complex, so there may be other alterations that may predict if AZD4547 is working.
- Of 21 patients dosed with AZD4547, seven had high FGFR and three of these patients (squamous NSCLC, breast and bladder cancer) had target lesion shrinkage or prolonged (≥24 weeks) disease stabilization.
- Further work is needed to better understand FGFR signaling.
<<<
Related Videos
Related Content
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
